...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Virology Journal >Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening
【24h】

Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening

机译：根据国际乳头瘤病毒DNA宫颈癌筛查要求的国际指导方针对宫颈样品进行HPVIR高危HPV检测的临床验证

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The indicating FTA card is a dry medium used for collection of cervical samples. HPVIR is a multiplex real-time PCR test that detects 12 high-risk human papillomavirus types (hrHPV) and provides single genotype information for HPV16, ??31, ??35, ??39, ??51, ??56, and???59 and pooled type information for HPV18/45 and HPV33/52/58. The aim of this study was to evaluate whether a strategy with cervical samples collected on the FTA card and subsequently analysed with the HPVIR test complies with the criteria of the international guidelines for a clinically validated method for cervical screening. We performed a non-inferiority test comparing the clinical sensitivity and specificity of the candidate test (FTA card and HPVIR) with a clinically validated reference test (Cobas? HPV test) based on liquid-based cytology (LBC) samples. Two clinical samples (LBC and FTA) were collected from 896 participants in population-based screening. For evaluation of the specificity we used 799 women without ≥ CIN2, and for clinical sensitivity we used 67 women with histologically confirmed ≥ CIN2. The reproducibility was studied by performing inter- and intra-laboratory tests of 558 additional clinical samples. The clinical sensitivity and specificity for samples collected on the FTA card and analysed using the HPVIR test were non-inferior to samples analysed with the Cobas? HPV test based on LBC samples (non-inferiority test score, p?=?1.0?×?10??2 and p?=?1.89?×?10??9, respectively). Adequate agreement of ?87% was seen in both the intra- and inter-laboratory comparisons. Samples collected on the indicating FTA card and analysed with HPVIR test fulfil the requirements of the international guidelines and can therefore be used in primary cervical cancer screening.
机译：指示性FTA卡是用于收集宫颈样本的干燥介质。 HPVIR是一种多重实时PCR测试，可检测12种高危型人乳头瘤病毒（hrHPV）并提供HPV16、31、35、39、51、56和56的单一基因型信息。 59和HPV18 / 45和HPV33 / 52/58的合并类型信息。这项研究的目的是评估在FTA卡上收集并随后通过HPVIR测试分析的宫颈样本的策略是否符合临床验证的宫颈筛查方法国际准则的标准。我们进行了一项非劣效性测试，将候选测试（FTA卡和HPVIR）的临床敏感性和特异性与基于液体细胞学（LBC）样品的临床验证参考测试（Cobas？HPV测试）进行了比较。在基于人群的筛查中，从896名参与者中收集了两个临床样本（LBC和FTA）。为了评估特异性，我们使用了799例CIN2不≥的女性，为了临床敏感性，我们使用了67例经组织学确认为CIN2的女性。通过对558个其他临床样品进行实验室间和实验室内测试来研究可重复性。在FTA卡上收集并通过HPVIR测试分析的样品的临床敏感性和特异性不亚于用Cobas？分析的样品。基于LBC样本的HPV测试（非自卑测验分数，p≥= 1.0××10 10 2和p≥= 1.89××10 10 9）。在实验室内和实验室间的比较中，均发现≥87％的一致性。在指示性FTA卡上收集并通过HPVIR测试分析的样品符合国际准则的要求，因此可用于原发性宫颈癌筛查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号